Regenxbio’s single-dose gene therapy shows 3-year durability in diabetic retinopathy trial
Regenxbio presented three-year durability data for Surabgene (lomparvovec) in non-proliferative diabetic retinopathy at the Retina Society 59th Annual Scientific Meeting in Los Angeles. In long-term follow-up from the Phase II ALTITUDE study (data as of 17 August 2026), a single in-office suprachoro
<p>Regenxbio presented three-year durability data for Surabgene (lomparvovec) in non-proliferative diabetic retinopathy at the Retina Society 59th Annual Scientific Meeting in Los Angeles. In long-term follow-up from the Phase II ALTITUDE study (data as of 17 August 2026), a single in-office suprachoro</p>